ArticleACS infectious diseases2026
Silymarin Attenuates Arthritis and Myositis in a Murine Model of Acute Infection by Chikungunya and Mayaro Viruses.
Article in ACS infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The alphaviruses chikungunya (CHIKV) and Mayaro (MAYV) are responsible for acute febrile illnesses often accompanied by severe and persistent joint and muscle pain. Due to the lack of specific treatment, research into antivirals against these emerging viruses is seen as an urgent need. Previous studies demonstrated that silymarin exhibits potent antiviral activity against CHIKV and MAYV. Then, given the promising antiviral profile of silymarin, and the prominent joint and muscle pain caused by these viruses, we evaluated whether silymarin could reverse these damages in a murine model of alphavirus-induced arthritis and myositis. BALB/c mice were infected with CHIKV or MAYV in the right hind paw pad, and treated groups received silymarin orally (200 mg/kg/day). Clinical observation revealed reduced paw edema in silymarin-treated animals. At 7 and 12 days postinfection (dpi), animals were euthanized and various tissues collected. In infected and treated animals, a greater than 90% reduction in CHIKV viral load was observed in the spleen (7 and 12 dpi), paw (7 dpi), soleus muscle, and liver (12 dpi). Similarly, for MAYV, a greater than 90% reduction in viral load was detected in the spleen (7 and 12 dpi), liver, quadriceps, soleus muscle (7 dpi), and paw (12 dpi). Histological analysis revealed reduced inflammatory infiltrates in the liver, paw, and muscles as well as a decrease in both the number and area of lymphoid nodules in the spleen (12 dpi). Furthermore, silymarin treatment reduced TNF-α levels by at least 2-fold in the paw (7 and 12 dpi) and quadriceps (12 dpi). These findings suggest that silymarin not only limits viral replication in key target tissues, including the spleen, liver, muscle, and paw, but also mitigates inflammation by reducing paw edema, inflammatory infiltrates in hepatic, musculoskeletal, and paw tissues, the number and area of lymphoid nodules in the spleen, and TNF-α levels in the quadriceps muscle and paw, thereby supporting its therapeutic potential against CHIKV and MAYV infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.